WO2014115206A1 - 組織透明化方法、組織透明化試薬及び組織観察方法 - Google Patents
組織透明化方法、組織透明化試薬及び組織観察方法 Download PDFInfo
- Publication number
- WO2014115206A1 WO2014115206A1 PCT/JP2013/006811 JP2013006811W WO2014115206A1 WO 2014115206 A1 WO2014115206 A1 WO 2014115206A1 JP 2013006811 W JP2013006811 W JP 2013006811W WO 2014115206 A1 WO2014115206 A1 WO 2014115206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- thiodiethanol
- glycerol
- procedure
- solvent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 140
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 39
- 238000009877 rendering Methods 0.000 title abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 150
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000007864 aqueous solution Substances 0.000 claims abstract description 47
- 150000005527 organic iodine compounds Chemical class 0.000 claims abstract description 44
- 239000003021 water soluble solvent Substances 0.000 claims abstract description 19
- 239000000243 solution Substances 0.000 claims description 59
- 210000004556 brain Anatomy 0.000 claims description 40
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 30
- 229930006000 Sucrose Natural products 0.000 claims description 30
- 239000005720 sucrose Substances 0.000 claims description 30
- 210000000278 spinal cord Anatomy 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 25
- 210000004204 blood vessel Anatomy 0.000 claims description 20
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 19
- 239000007850 fluorescent dye Substances 0.000 claims description 19
- 238000005352 clarification Methods 0.000 claims description 17
- 239000011630 iodine Substances 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 15
- 238000002372 labelling Methods 0.000 claims description 13
- 210000004072 lung Anatomy 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 238000001215 fluorescent labelling Methods 0.000 claims description 9
- 210000002216 heart Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 abstract description 65
- 239000003960 organic solvent Substances 0.000 abstract description 8
- 239000012046 mixed solvent Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 231100001261 hazardous Toxicity 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 124
- 241000700159 Rattus Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108091006047 fluorescent proteins Proteins 0.000 description 18
- 102000034287 fluorescent proteins Human genes 0.000 description 18
- 238000007654 immersion Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000010186 staining Methods 0.000 description 11
- 229930040373 Paraformaldehyde Natural products 0.000 description 10
- 239000003125 aqueous solvent Substances 0.000 description 10
- 238000002073 fluorescence micrograph Methods 0.000 description 10
- 229920002866 paraformaldehyde Polymers 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 230000005284 excitation Effects 0.000 description 8
- 229960000780 iomeprol Drugs 0.000 description 8
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000010826 Nissl staining Methods 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000012758 nuclear staining Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 108010014765 tomato lectin Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940099373 sudan iii Drugs 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- QPHJQCAPTXSDDP-UHFFFAOYSA-N 2-phenyl-2,7-diazaspiro[4.4]nonane Chemical compound C1NCCC11CN(C=2C=CC=CC=2)CC1 QPHJQCAPTXSDDP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- WWVAPFRKZMUPHZ-UHFFFAOYSA-N Iodoxamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I WWVAPFRKZMUPHZ-UHFFFAOYSA-N 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 1
- ZFHZUGUCWJVEQC-FPUQOWELSA-M Ipodate Sodium Chemical compound [Na+].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I ZFHZUGUCWJVEQC-FPUQOWELSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000572987 Mus musculus POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000238633 Odonata Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- QEPMPXAUMUWNNO-UHFFFAOYSA-N bis(methylsulfanyl)methyl-trimethylsilane Chemical compound CSC(SC)[Si](C)(C)C QEPMPXAUMUWNNO-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960005223 diatrizoic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000009688 glial response Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 229960004901 iodamide Drugs 0.000 description 1
- 229960002487 iodoxamic acid Drugs 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960000929 iotalamic acid Drugs 0.000 description 1
- 229960003182 iotrolan Drugs 0.000 description 1
- 229960000506 iotroxic acid Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
Definitions
- the present invention relates to a tissue clearing method, a tissue clearing reagent, and a tissue observation method. More specifically, the present invention relates to a tissue transparency method and the like that can make a tissue transparent easily and safely without causing the change.
- the internal tissue of an organ has been observed by mechanically slicing a fixed and embedded organ (or an organ piece) to prepare a tissue section and observing it with an optical microscope.
- it has become possible to obtain an observation image of an internal tissue by optically “cutting” an organ using a confocal laser microscope or a multiphoton excitation microscope.
- the above-described mechanical method requires a lot of continuous tissue sections and the accumulation of those fluorescence images, which is very labor intensive. .
- the optical method since light is scattered inside the organ, there is a problem that the acquisition of a fluorescence image becomes difficult as the site to be observed becomes deeper from the organ surface (observation depth limit).
- the observation depth limit is generally about 0.15 mm with a confocal laser microscope and about 4 mm at maximum with a two-photon excitation microscope.
- the thickness of the surface cortex is about 1 mm. Therefore, in order to observe the hippocampus and thalamus inside the cortex, the observation depth limit is several millimeters. It is necessary to spread.
- Non-Patent Document 1 reports that the brain and spinal cord were made transparent by a technique using tetrahydrofuran.
- Patent Document 1 and Non-Patent Document 2 describe that the brain can be made transparent by a technique using high-concentration urea (Scale method).
- Non-Patent Document 4 describes that tissue such as dragonfly thoracic ganglion and squid skin can be made transparent to a thickness of about 0.6 mm using 2,2′-thiodiethanol.
- Non-Patent Document 5 preceding this describes the use of 2,2′-thiodiethanol as an encapsulating agent.
- Non-Patent Document 1 Although the transparency method described in Non-Patent Document 1 is excellent in transparency, it is necessary to use an organic solvent containing dichloromethane that is suspected of carcinogenicity. There's a problem. In addition, due to the process of dehydrating the fixed organ and the effect of the clearing reagent itself, there is a problem that the organ hardens or the fluorescent signal of the fluorescent protein labeled in the organ disappears or attenuates.
- Non-Patent Document 2 since the transparency method (Scale method) disclosed in Non-Patent Document 2 can use a water-soluble reagent that does not require dehydration of biological material, the above-described problem of the method described in Non-Patent Document 1 is eliminated. It can be solved.
- the Scale method requires a long time (about two weeks) for the treatment for transparency, and the degree of transparency is insufficient.
- the thickness of the tissue that can be made transparent is only about 0.6 mm, and the observation depth is insufficient (see Non-Patent Document 4).
- 2,2′-thiodiethanol was used at a high concentration of 80 to 85% or more, some fluorescent proteins such as GFP lost or attenuated the fluorescent signal (see Non-Patent Document 5). .
- the present invention provides a technique capable of sufficiently transparentizing various organs without causing a change by a simple operation without using a toxic or dangerous organic solvent. Main purpose.
- the present invention provides a tissue clearing method including a procedure of immersing a tissue in a water-soluble solvent having a refractive index of 1.4 to 1.7.
- a mixture of 2,2′-thiodiethanol, glycerol, and a nonionic organic iodine compound aqueous solution is preferably used as the water-soluble solvent.
- the volume ratios of 2,2′-thiodiethanol, glycerol and aqueous solution of nonionic organic iodine compound having an iodine content of 40% in the aqueous solvent are 10 to 50%, 1 to 20% and 10 to 70%, respectively. It is said.
- aqueous solvent a mixed solution of 2,2′-thiodiethanol and a nonionic organic iodine compound aqueous solution may be used.
- the volume ratio of the aqueous solution of 2,2′-thiodiethanol and nonionic organic iodine compound having an iodine content of 40% in the aqueous solvent is set to 20 to 80% and 80 to 20%.
- a mixed liquid of 2,2′-thiodiethanol and glycerol may be used as the aqueous solvent.
- the volume ratio of 2,2′-thiodiethanol and glycerol in the aqueous solvent is 70 to 95% and 5 to 30%.
- the aqueous solvent contains 2,2'-thiodiethanol and a nonionic organic iodine compound It is preferable to use a mixed solution of an aqueous solution or a solution obtained by adding glycerol thereto.
- the water-soluble solvent can further contain an aqueous sucrose solution depending on the target organ.
- the present invention also provides a tissue clearing reagent comprising a water-soluble solvent having a refractive index of 1.4 to 1.7.
- the tissue clearing reagent includes a water-soluble solvent containing 2,2′-thiodiethanol and at least one of glycerol and a nonionic organic iodine compound.
- the tissue clearing reagent is more preferably a mixed solution of 2,2′-thiodiethanol and a nonionic organic iodine compound aqueous solution or a mixed solution of 2,2′-thiodiethanol and glycerol, depending on the target organ.
- tissue clearing reagent may further contain an aqueous sucrose solution depending on the target organ.
- the present invention also provides a tissue observation method including a clearing procedure in which the tissue is immersed in a water-soluble solvent having a refractive index of 1.4 to 1.7.
- the tissue observation method includes a labeling procedure for fluorescently labeling the tissue, the clearing procedure for immersing the tissue after fluorescent labeling in the solvent, and the fluorescent labeling in the tissue after clearing A detection procedure for detecting fluorescence emitted from.
- the tissue observation method includes the clearing procedure for immersing the tissue in the solvent, a labeling procedure for fluorescently labeling the tissue after clearing, and the fluorescent labeling in the tissue after clearing and fluorescent labeling. Detecting procedures for detecting the emitted fluorescence. In this tissue observation method, observation with a fluorescence microscope, a fluorescent stereomicroscope, a confocal microscope, or a multiphoton microscope can be suitably employed in the detection procedure.
- tissue is used synonymously with “organ” and broadly means living tissue.
- tissue or organ
- tissue is particularly limited to brain, spinal cord, liver, spleen, kidney, lung, heart, blood vessel, skin, subcutaneous tissue, intestine, adipose tissue, lymph node, muscle, tendon and cancer. Included without.
- the bone can be a target of the tissue clearing method and the like according to the present invention as long as it is a bone in which calcification has not progressed, such as a fetal or neonatal bone.
- the present invention provides a technique capable of sufficiently transparentizing various organs without causing a change by a simple operation without using a toxic or dangerous organic solvent.
- FIG. 5 is a drawing-substituting photograph showing a fluorescence image obtained by transparentizing a rat spinal cord labeled with a nerve axon. It is a drawing substitute photograph which shows the rat injury spinal cord which became transparent. It is a drawing substitute photograph which shows the three-dimensional fluorescence image of the rat injury spinal cord which became transparent.
- FIG. 5 is a drawing-substituting photograph showing a Nissl-stained image of a transparent rat brain. It is a drawing substitute photograph which shows the transparent rat individual
- FIG. 3 is a drawing-substituting photograph showing a cancer that has been cleared by a tissue clearing reagent containing a nonionic organic iodine compound. It is a drawing substitute photograph which shows the mouse brain which became transparent. It is a drawing-substituting photograph showing a fluorescent image obtained by transparentizing a mouse brain fluorescently labeled with a cerebral blood vessel. It is a drawing substitute photograph which shows the result of immersing a rat brain in a thiodiethanol single solution for comparison.
- the tissue clearing method and the tissue observation method according to the present invention include a clearing procedure for immersing the tissue in a water-soluble solvent (tissue clearing reagent) having a refractive index of 1.4 to 1.7. To do.
- the refractive index of the water-soluble solvent is more preferably 1.50 to 1.52.
- the target organ is not particularly limited, but it is the brain, spinal cord, liver, spleen, kidney, lung, heart, blood vessel, skin, subcutaneous tissue. Intestines, adipose tissue, lymph nodes, muscles, tendons and cancer, and bones.
- thiodiethanol 2,2′-thiodiethanol
- a tissue having a thickness of 1 mm or more, specifically, a thickness of about 1 mm to 2 cm is used. It was revealed for the first time that even organizations can be transparent.
- tissue clearing reagent The refractive index of the water-soluble solvent (hereinafter also referred to as “tissue clearing reagent”) can be appropriately set within the above numerical range according to the target organ.
- tissue clearing reagent satisfying the above refractive index, mixing of thiodiethanol (refractive index 1.52) and nonionic organic iodine compound aqueous solution (refractive index of about 1.51 of aqueous solution with 40% iodine content) Liquid, or a mixed liquid of thiodiethanol and glycerol (refractive index: 1.474), more preferably a mixed liquid of thiodiethanol, glycerol, and a nonionic organic iodine compound aqueous solution.
- the tissue clearing reagent may further contain an aqueous sucrose solution as desired according to the target organ.
- the volume ratio of the thiodiethanol, glycerol, and the nonionic organic iodine compound aqueous solution having an iodine content of 40% in the aqueous solvent is 10 to 50 respectively. %, 1-20% and 10-70%.
- the volume ratio of the thiodiethanol and the nonionic organic iodine compound aqueous solution having an iodine content of 40% in the aqueous solvent is 20 to 80%, 80%. ⁇ 20%. Furthermore, when a mixed solution of thiodiethanol and glycerol is used, the volume ratio of thiodiethanol and glycerol in the aqueous solvent is 70 to 95% and 5 to 30%.
- the addition volume of one or more of thiodiethanol, glycerol, and nonionic organic iodine compound aqueous solution may be reduced according to the addition volume of the sucrose aqueous solution.
- the volume ratio of thiodiethanol, glycerol, nonionic organic iodine compound aqueous solution and sucrose aqueous solution in the tissue clearing reagent can be adjusted in a wide range depending on the degree of transparency desired for the target organ.
- the transparency of the organ can be further increased by increasing the volume of thiodiethanol.
- the target organ is the lung
- the tissue clearing reagent may be a mixed solution of thiodiethanol and a nonionic organic iodine compound aqueous solution, but in order to obtain a high degree of transparency and high retention of fluorescent protein fluorescence signals, Most preferably, a reagent obtained by adding glycerol to an aqueous solution of thiodiethanol and a nonionic organic iodine compound is used.
- a mixed solution of thiodiethanol and glycerol is used as a tissue clearing reagent, fluorescent protein can be added even under conditions of a relatively high thiodiethanol concentration (volume ratio higher than 80%) by adding glycerol. It becomes possible to make the organ transparent while suppressing the disappearance or attenuation of the fluorescence signal.
- nonionic organic iodine having a refractive index corresponding to the refractive index range (1.4 to 1.7) (refractive index of about 1.51 of an aqueous solution having an iodine content of 40%).
- the amount of thiodiethanol used can be reduced to about 10 to 50%, preferably about 20 to 50%.
- the fluorescent signal of the fluorescent protein can be kept at a good level even after the clearing.
- the volume ratio is preferably 10 to 80%.
- the iodine content (mass / volume%) can be calculated from the mass ratio of iodine atoms to the total mass of the nonionic organic iodine compound and the concentration (mass / volume%) of the nonionic organic iodine compound in the aqueous solution.
- the iodine content of nonionic organic iodine compound aqueous solution can be changed suitably, and is not restricted to 40%.
- the volume ratio of the nonionic organic iodine compound aqueous solution in the tissue clearing reagent can also be appropriately adjusted according to the iodine content.
- Nonionic organic iodine compound for example, a nonionic iodine contrast agent obtained by imparting hydrophilicity to an organic compound containing iodine atoms at a high concentration can be used.
- Nonionic iodinated contrast agents include diatrizoic acid, amidotrizoic acid, ioxagric acid, ioxirane, iotalamic acid, iotroxic acid meglumine, iotrolan, iopanoic acid, iopamidol, iopromide, iohexol, iomeprol, iopodate sodium, metrizoic acid, iodamide, Conventionally known contrast agents such as iodoxamic acid and iodized poppy oil fatty acid ethyl ester can be mentioned.
- the volume ratio of a 30% sucrose aqueous solution is preferably 2 to 10%.
- sucrose aqueous solution By adding a sucrose aqueous solution, the transparency of the tissue clearing reagent can be improved and the transparency of the organ can be increased. The reason for this is not limited by logic, but it is presumed that the addition of sucrose can prevent cell membranes and cytoplasm turbidity due to excessive tissue fixation.
- a suitable example of the composition of the tissue clearing reagent is a mixed solution in which the volume ratio of the aqueous solution of thiodiethanol, glycerol and nonionic organic iodine compound having an iodine content of 40% is 45: 5: 50.
- Dimethyl sulfoxide may be added to the tissue clearing reagent.
- DMSO contributes to increasing the transparency of the organ by improving the penetration of the tissue clearing reagent.
- concentration of DMSO added is, for example, 0.1 to 10%.
- any one or more of thiodiethanol, glycerol, nonionic organic iodine compound aqueous solution and sucrose aqueous solution may be reduced according to the DMSO addition volume.
- the water-soluble solvent satisfying the refractive index of 1.4 to 1.7 in addition to the mixed solvent described above, polyhydric alcohols, polyhydric alcohol derivatives, nitrogen-containing solvents, alcohols, sulfur-containing solvents, and these In some cases, a mixed solvent or the like can be used. In addition, other monosaccharides and / or polysaccharides other than sucrose may be added to the water-soluble solvent, but sucrose is considered preferable from the viewpoint of high solubility in water.
- the organ is clarified by immersing it in a tissue clarification reagent for a predetermined time.
- the immersion is preferably performed at about 4 to 60 ° C., particularly preferably at about 20 to 42 ° C.
- an aqueous solution having a concentration of about 30% is preferably used as the sucrose aqueous solution.
- the immersion time varies depending on the target organ, but is, for example, 24 hours to 6 days. As an example, when the target organ is a brain, spinal cord, heart, skin, or muscle, immersion is performed for about 4 to 6 days. Further, when the target organ is liver, kidney, lung, blood vessel, lymph node or cancer, immersion for 24 hours to 3 days is preferable.
- immersion in a pretreatment solution with a reduced volume ratio of thiodiethanol may be performed.
- the pretreatment solution a plurality of solutions having different thiodiethanol volume ratios may be used.
- the organs are immersed for a predetermined time in order from the pretreatment solution having a smaller thiodiethanol volume ratio.
- a treatment solution containing sucrose may be used in the previous step, and finally a treatment solution not containing sucrose may be used, which is effective when precipitation of sucrose becomes a problem. is there.
- Such multi-stage (two or more stages) pretreatment is particularly effective when a mixed solution of thiodiethanol and glycerol and, if necessary, a sucrose aqueous solution is used as a final solution. This is not always necessary when using a mixed solution containing a nonionic organic iodine compound aqueous solution as the solution.
- the brain When using a tissue clarification reagent containing a nonionic organic iodine compound aqueous solution, the brain can be clarified in about 3 to 4 days and all other tissues except bones can be clarified in about 2 days by one-step pretreatment.
- Organic iodine compound aqueous solution: 45: 5: 50 solution is used.
- the pretreatment liquid is immersed, for example, at 4 ° C. to 25 ° C. for 24 hours, and the final solution is immersed, for example, at 4 ° C. to 25 ° C. for 24 to 48 hours.
- tissue transparency method a sufficient degree of organ transparency can be obtained in a shorter operation than in the conventional method.
- tissue clearing method an organ can be cleared by immersion in a water-soluble solvent without using a toxic or dangerous organic solvent (see Examples described later). Therefore, the tissue clearing method according to the present invention is free from the problems of flammability of organic solvents and the difficulty of waste liquid management, and has high safety.
- the tissue clearing method according to the present invention since no organic solvent is used, the fluorescence signal of the fluorescent protein labeled in the organ disappears due to the process of dehydrating the fixed organ or the effect of the tissue clearing reagent itself. The fluorescence of almost all the fluorescent labels is retained without being attenuated. Furthermore, in the tissue clearing method according to the present invention, an effect of preventing the deterioration (discoloration) of the fluorescent protein by glycerol added in the water-soluble solvent can be obtained.
- an immobilization procedure using a conventionally known histopathological technique may be performed before the above-described tissue clearing procedure.
- the organ was perfused and fixed with a formalin solution (10% neutral formalin solution, 4% paraformaldehyde buffer solution), and then the organ was removed, and the solution was further removed for about 24 hours or more.
- a dipping technique can be employed.
- the tissue observation method it is possible to detect the fluorescence emitted from the fluorescent label in the cleared tissue by performing the above-described transparentization procedure after fluorescently labeling the tissue.
- the tissue clearing method according to the present invention can retain the fluorescence of almost all the fluorescent labels and can prevent the deterioration (fading) of the fluorescent protein. Therefore, by the multiple staining using a plurality of fluorescent labels. It is also suitable for tissue observation.
- the labeling procedure includes a method of expressing a fluorescent protein in a tissue (for example, nerve fiber) by gene transfer, a method of injecting a fluorescent protein or fluorescent dye into an organ (for example, a blood vessel), and an antibody labeled with the fluorescent protein or fluorescent dye to a cell. It can be performed by a conventionally known method such as a method of combining.
- the fluorescent dye refers to a low molecular compound (for example, fluorescein) having a smaller molecular weight than a fluorescent protein such as GFP.
- Conventionally known substances can be used for the fluorescent protein and the fluorescent dye.
- the detection procedure of the fluorescence emitted from the fluorescent label in the tissue after clarification is not particularly limited, and a conventionally known fluorescence detection means such as observation with a fluorescence microscope, a fluorescence stereomicroscope, a confocal microscope, or a multiphoton microscope is used. Can be done. According to the tissue clearing method according to the present invention, high transparency of the organ can be achieved, so that the observation depth limit by the confocal microscope or the multiphoton microscope can be extended to several millimeters.
- tissue observation method various organs can be transparentized without hardening, swelling, and weakening by the tissue transparency procedure (see Examples described later). Therefore, unlike conventional methods such as the Scale method, observation can be performed while maintaining the state of the extracted organ. Moreover, since the organ can be sliced easily with a knife or the like after the transparentization, the tissue staining can be performed after the transparentization for observation.
- the tissue observation method according to the present invention since the fluorescence signal of the fluorescent protein labeled in the organ does not disappear or attenuate, high-accuracy fluorescence observation is possible.
- the tissue observation method according to the present invention is effective when observing deep organs with very weak excitation energy using a multiphoton microscope.
- the tissue after the transparency is fluorescently labeled, and fluorescence emitted from the fluorescent label in the cleared tissue may be detected. Is possible.
- the tissue clearing method according to the present invention can be made transparent without excessively swelling or weakening the organ, the transparent organ can be sliced. For this reason, if the organ piece sliced after clearing is stained by an immunohistochemical technique using a fluorescently labeled antibody, the tissue after clearing can be fluorescently labeled.
- the transparent organ or organ piece can be subjected to conventionally known histopathological staining using various staining solutions.
- an organ in the tissue clearing method according to the present invention, can be made transparent while retaining fat, so that fat staining such as Sudan III staining, Oil Red staining, and Sudan Black staining can also be performed.
- the organ is excised and clarified, and the clarified tissue is further fluorescently labeled by immunostaining and emitted from two or more fluorescent labels in the clarified tissue.
- Applications such as detecting the fluorescence emitted are also possible.
- FIG. 1B A indicates the result obtained by the Scale method described in Non-Patent Document 2.
- the spinal cord could be made transparent with higher transparency than the Scale method (A).
- the Scale method (A) has a problem that the spinal cord swells twice, whereas the tissue transparency method (B) according to the present invention does not cause such a problem.
- Example 2 Clarification of rat brain> Rat brain (tissue thickness 6 mm) was fixed and clarified by the procedure described in Example 1.
- FIG. 2B A indicates the result obtained by the Scale method described in Non-Patent Document 2.
- the brain can be made transparent with higher transparency than the Scale method (A).
- the scale method (A) has a problem that the brain is significantly swollen and easily collapses when pressed with a finger, whereas the tissue clearing method (B) according to the present invention is swollen and weakened. Did not occur.
- Example 3 Fluorescence observation of rat spinal cord> Transgenic rats expressing the fluorescent protein VENUS in nerve axons were created.
- Non-patent document 3 ("Visual properties of transgenic rats harboring the channelrhodopsin-2 gene regulated by the thy-1.2 promoter.” PLoS ONE, 2009, Vol.4, No.11, e7679) The method was used. The spinal cord fixed and transparentized by the procedure described in Example 1 was observed with a confocal microscope (Zeiss, LSA-700).
- the acquired fluorescence image is shown in FIG. 3A.
- B is an enlarged image of a region surrounded by a dotted line in A.
- Example 4 Observation of rat injured spinal cord> The spinal cord was damaged by half-cutting the dorsal side of the 12th thoracic spinal cord of the above-described transgenic rat with sharp scissors, and then the wound was closed. After 4 weeks, the spinal cord was fixed and cleared by the procedure described in Example 1. The clear spinal cord was observed with a multiphoton excitation microscope (Nikon, A1MP).
- FIG. 4 In the spinal cord after transparency, as shown in FIG. 4, it was possible to see through the site damaged from the outside.
- the damaged part is visually colored brown by hemosiderin.
- the acquired three-dimensional fluorescence image is shown in FIG. In the image, green indicates a signal from a nerve axon, and blue indicates a second harmonic generation ( ⁇ ⁇ SHG) signal. Fluorescence due to SHG from collagen is observed at the damaged site, and it is confirmed that collagen is grown and fibrosis occurs at the same site.
- mice Observation of mouse encephalomyelitis> Experimental encephalomyelitis was induced in mice.
- the mouse ridge was subcutaneously injected with an inflammation-inducing MOG peptide emulsion, and after 30 days, it was fixed by perfusion with 4% paraformaldehyde buffer, and then the cerebral spinal cord was excised and further immersed and fixed in the same solution for 24 hours.
- the cerebral spinal cord after transparency was observed with a multiphoton excitation microscope.
- FIG. 6 shows the spinal cord (A) and the brain (B) after the transparency.
- the final degree of organ transparency was deliberately suppressed by using a water-soluble solvent containing thiodiethanol and glycerol as tissue clearing reagents and no sucrose aqueous solution.
- FIG. 6B the lesion can be confirmed as a cloudy part in the brain stem.
- FIG. 7 shows the acquired three-dimensional fluorescence image. In the image, red is a blood vessel, and green is a fluorescent image of bone marrow-derived cells.
- the fluorescent labeling of blood vessels was performed by injecting tomato lectin conjugated with a fluorescent reagent into the blood vessels of animals.
- fluorescent labeling of bone marrow-derived cells was performed using a fluorescently labeled anti-F4 / 80 antibody.
- FIG. 8A shows the lung after clearing.
- B is an image obtained by reversing the gradation of the image of A.
- the bronchi can be seen through from the outside in the lung after the transparency.
- FIG. 9 shows a three-dimensional image of the acquired alveolar blood vessel.
- Example 7 Observation of cancer> Human lung cancer cells into which GFP had been introduced were transplanted subcutaneously into nude mice, and after 60 days, cancer tissues (5 mm square) were excised and fixed by immersion in 4% paraformaldehyde buffer for 24 hours. Clarification was performed by the procedure described in Example 1. The cleared cancer was observed with a multiphoton excitation microscope.
- FIG. 10 shows the cancer after clearing.
- a three-dimensional fluorescence image of cancer is shown in FIG. 11A.
- FIG. 11B is a fluorescence observation image of cancer that has been made transparent by the Scale method.
- the observation depth limit was about 100 ⁇ m, tumor blood vessels could not be depicted, and the distribution of tumor cells (green in the image) was unclear.
- the tissue clearing method (A) according to the present invention the observation depth limit was 1000 ⁇ m or more, tumor blood vessels (red in the image) could be drawn, and the distribution of tumor cells was also confirmed. It was also found that the fluorescence signal of GFP was well retained.
- Example 8 Clarification of rat heart and mouse liver>
- the results are shown in FIGS.
- the arrow in FIG. 12 indicates the aorta.
- the arrow in FIG. 13 indicates the portal vein.
- Example 9 Dyeing after clearing> The rat brain clarified in Example 2 was sliced and subjected to immunostaining, fat staining, nuclear staining, and Nissl staining for glial fibrillary acidic protein (GFAP).
- GFAP glial fibrillary acidic protein
- Immunostaining was performed using a commercially available detection kit using an anti-GFAP antibody, an enzyme (peroxidase) and a dye (diaminobenzidine tetrahydrochloride). Sudan III was used for fat staining. DAPI was used for nuclear staining. Toluidine blue was used for Nissl staining.
- FIGS. FIG. 14 shows immunostained images of cerebellar Bergmann glia cells that are positive for GFAP
- FIG. 15 shows the results of fat staining
- FIG. 16 shows nuclear staining
- FIG. 17 shows the results of Nissl staining.
- an excellent deep part drawing property is realized by the transparency. It can also be confirmed that the target cerebellar white matter, cell nucleus, and nerve cell are stained in fat staining, nuclear staining, and Nissl staining, respectively.
- Example 11 Examination of organic iodine compound> Human lung cancer cells transfected with GFP were transplanted subcutaneously into nude mice and allowed to grow for 4 weeks. Tomato lectin bound with a fluorescent reagent was injected into the blood vessel of the animal and then fixed by perfusion with 4% paraformaldehyde buffer. The cancer tissue was excised and fixed by immersion in 4% paraformaldehyde buffer for 24 hours.
- thiodiethanol: glycerol: iomeprol 50: 5: 45
- A shows cancer tissue after fixation with 4% paraformaldehyde buffer.
- the blood vessel fluorescently labeled with tomato lectin in the cancer tissue after clarification was observed with a multiphoton excitation microscope.
- the inside could not be observed at all because of the connective tissue coating on the surface of the cancer tissue.
- the observation depth limit was about 800 ⁇ m.
- the cancer tissue after clearing shown in B it was possible to visualize tumor blood vessels exceeding the detection limit of about 1800 ⁇ m of the microscope, and attenuation of the fluorescence signal from GFP of the cancer cells was not observed.
- Example 13 Fluorescence observation of mouse brain blood vessel> EGFP was expressed in mouse brain blood vessels using a retroviral vector expressing EGFP. The brain that had been fixed and cleared in the same manner as in Example 12 was observed with a confocal microscope (Zeiss, LSA-700).
- the acquired fluorescent image is shown in FIG.
- cerebral blood vessels fluorescently labeled with EGFP could be observed with high accuracy.
- FIG. A shows the brain after fixation with 4% paraformaldehyde buffer.
- B shows the brain immersed in the thiodiethanol single solution.
- tissue clearing method According to the tissue clearing method according to the present invention, various organs can be sufficiently transparent without causing a change by a simple operation without using a toxic or dangerous organic solvent. Therefore, the tissue clearing method according to the present invention can be used for observing the internal tissue of an organ in various fields such as pathological analysis, evaluation of drug efficacy, screening for cancer metastasis, and the like without performing complicated tissue section preparation. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
この組織透明化方法において、前記水溶性溶媒には、2,2´-チオジエタノールとグリセロールと非イオン性有機ヨウ素化合物水溶液との混合液が好適に用いられる。この場合、水性溶媒中の2,2´-チオジエタノール、グリセロール及びヨウ素含有量40%の非イオン性有機ヨウ素化合物水溶液の容量比は、それぞれ10~50%、1~20%及び10~70%とされる。
また、前記水性溶媒として、2,2´-チオジエタノールと非イオン性有機ヨウ素化合物水溶液の混合液を用いることもできる。この場合、水性溶媒中の2,2´-チオジエタノール及びヨウ素含有量40%の非イオン性有機ヨウ素化合物水溶液の容量比は、20~80%、80~20%とされる。
さらに、前記水性溶媒として、2,2´-チオジエタノールとグリセロールとの混合液を用いてもよい。この場合、水性溶媒中の2,2´-チオジエタノール及びグリセロールの容量比は、70~95%、5~30%とされる。
水性溶媒中の2,2´-チオジエタノールの濃度を抑制して蛍光タンパク質の蛍光シグナルの消失又は減衰を防止するため、水性溶媒には、2,2´-チオジエタノールと非イオン性有機ヨウ素化合物水溶液の混合液あるいはこれにグリセロールを加えたものを用いることが好ましい。
加えて、前記水溶性溶媒は、対象とする臓器に応じて、さらにスクロース水溶液を含むことができる。
また、組織透明化試薬は、対象とする臓器に応じて、さらにスクロース水溶液を含んでいてもよい。
この組織観察方法は、具体的には、前記組織を蛍光標識する標識手順と、蛍光標識後の前記組織を前記溶媒中に浸漬する前記透明化手順と、透明化後の組織中の前記蛍光標識から発せられる蛍光を検出する検出手順と、を含むことができる。
また、この組織観察方法は、前記組織を前記溶媒中に浸漬する前記透明化手順と、透明化後の組織を蛍光標識する標識手順と、透明化及び蛍光標識後の組織中の前記蛍光標識から発せられる蛍光を検出する検出手順と、を含むことができる。
この組織観察方法では、前記検出手順において、蛍光顕微鏡、蛍光実体顕微鏡、共焦点顕微鏡又は多光子顕微鏡による観察を好適に採用できる。
本発明に係る組織透明化方法及び組織観察方法は、屈折率が1.4~1.7である水溶性溶媒(組織透明化試薬)中に組織を浸漬する透明化手順を含むことを特徴とする。水溶性溶媒の屈折率は、より好ましくは1.50~1.52とされる。
本発明に係る組織透明化方法及び組織観察方法において、対象とする臓器(あるいは臓器片)は、特に限定されないが、脳、脊髄、肝臓、脾臓、腎臓、肺、心臓、血管、皮膚、皮下組織、腸、脂肪組織、リンパ節、筋肉、腱及び癌、並びに骨などとされる。本発明では、2,2´-チオジエタノール(以下、単に「チオジエタノール」と称する)にグリセロールを組み合わせて用いることで、1mm以上の厚さの組織、具体的には1mm~2cm程度の厚みの組織であっても、透明化できることが初めて明らかにされた。
水溶性溶媒(以下、「組織透明化試薬」とも称する)の屈折率は、対象臓器に応じて上記数値範囲内で適宜設定され得る。上記屈折率を満たす組織透明化試薬の好適な例として、チオジエタノール(屈折率1.52)と非イオン性有機ヨウ素化合物水溶液(ヨウ素含有量40%の水溶液の屈折率約1.51)の混合液、あるいはチオジエタノールとグリセロール(屈折率1.474)との混合液が挙げられ、より好ましくはチオジエタノールとグリセロールと非イオン性有機ヨウ素化合物水溶液との混合液が挙げられる。また、組織透明化試薬は、対象とする臓器に応じて所望により、さらにスクロース水溶液を含んでいてもよい。
また、チオジエタノールと非イオン性有機ヨウ素化合物水溶液の混合液を用いる場合、水性溶媒中のチオジエタノール及びヨウ素含有量40%の非イオン性有機ヨウ素化合物水溶液の容量比は、20~80%、80~20%とされる。
さらに、チオジエタノールとグリセロールとの混合液を用いる場合、水性溶媒中のチオジエタノール及びグリセロールの容量比は、70~95%、5~30%とされる。
スクロース水溶液を添加する場合には、スクロース水溶液の添加容量に応じて、チオジエタノール、グリセロール及び非イオン性有機ヨウ素化合物水溶液のいずれか1以上の添加容量を減らせばよい。
臓器は組織透明化試薬中に所定時間浸漬することにより透明化される。浸漬は4~60℃程度にて行うことが好ましく、20~42℃程度にて行うことが特に好ましい。試薬を室温以上に加温することで、試薬の粘性が低下し、臓器内への浸透度が向上する。低温度下でのスクロースの析出を防止するため、スクロース水溶液には30%程度の濃度の水溶液を用いることが好ましい。浸漬する時間は対象臓器によって異なるが、例えば24時間~6日間である。一例として、対象臓器が脳、脊髄、心臓、皮膚又は筋肉である場合、4~6日程度の浸漬が行われる。また、対象臓器が肝臓、腎臓、肺、血管、リンパ節又は癌である場合、24時間~3日間の浸漬が好ましい。
本発明に係る組織透明化方法及び組織観察方法では、上述の組織透明化手順の前に、従来公知の病理組織学的手法による固定化手順を行ってもよい。また、固定化手順には、必要に応じて従来公知の脱脂処理等を組み合わせてもよい。
[透明化前の蛍光標識]
本発明に係る組織観察方法では、組織を蛍光標識した後に、上述の透明化手順を行って、透明化された組織中の蛍光標識から発せられる蛍光を検出することが可能である。上述のように、本発明に係る組織透明化方法は、ほぼすべての蛍光標識の蛍光を保持でき、かつ、蛍光タンパク質の劣化(退色)を防止できるため、複数の蛍光標識を用いた多重染色による組織観察にも好適である。
また、本発明に係る組織観察方法では、上述の透明化手順を行った後に、透明化後の組織を蛍光標識して、透明化された組織中の蛍光標識から発せられる蛍光を検出することも可能である。
4%パラフォルムアルデヒド緩衝液で灌流固定した後にラット脊髄を摘出し、さらに同溶液に24時間浸漬して固定した。固定後の脊髄(径3mm)を、チオジエタノール:グリセロール:スクロース=20:40:40の溶液、50:40:10の溶液、70:25:5の溶液の各前処理溶液に順にそれぞれ24時間ずつ浸漬した後、90:5:5の最終溶液に24時間浸漬して透明化した。
ラット脳(組織厚6mm)を実施例1に記載の手順で固定し透明化した。
神経軸索に蛍光タンパク質VENUSを発現するトランスジェニックラットを作成した。トランスジェニックラットの作成は、非特許文献3("Visual properties of transgenic rats harboring the channelrhodopsin-2 gene regulated by the thy-1.2 promoter." PLoS ONE, 2009, Vol.4, No.11, e7679)記載の手法により行った。実施例1に記載の手順で固定し透明化した脊髄を共焦点顕微鏡(Zeiss, LSA-700)により観察した。
上述のトランスジェニックラットの第12胸髄の背側を鋭利なハサミで半切して脊髄を損壊した後、傷口を閉じた。4週間後に、実施例1に記載の手順で脊髄を固定し透明化した。透明化後の脊髄を多光子励起顕微鏡(Nikon, A1MP)により観察した。
マウスに実験的脳脊髄炎を誘起した。マウス尾根部に炎症誘起MOGペプチドエマルジョンを皮下注射し、30日後に4%パラフォルムアルデヒド緩衝液で灌流固定した後に脳脊髄を摘出し、さらに同溶液に24時間浸漬して固定した。固定後の脳脊髄を、チオジエタノール:グリセロール=20:80の溶液、50:50の溶液、70:30の溶液の各前処理溶液に順にそれぞれ24時間ずつ浸漬した後、90:10の最終溶液に24時間浸漬して透明化した。透明化後の脳脊髄を多光子励起顕微鏡により観察した。
実施例1に記載の手順でマウス肺(下葉、縦:横:厚み=7mm:5mm:5mm)を固定し透明化した。透明化後の肺を多光子励起顕微鏡により観察し、肺胞血管の3次元構造を構築した。
GFPを遺伝子導入したヒト肺癌細胞をヌードマウスの皮下に移植し、60日後に癌組織(5mm角)を摘出し、4%パラフォルムアルデヒド緩衝液に24時間浸漬して固定した。実施例1に記載の手順により透明化を行った。透明化後の癌を多光子励起顕微鏡により観察した。
ラットの心臓(1.2cm角)及びマウスの肝臓(縦:横:厚み=1cm:1cm:6mm)を実施例1に記載の手順で固定し透明化した。結果を図12、図13に示す。図12中矢印は、大動脈を示す。図13中矢印は、門脈を示す。
実施例2で透明化したラット脳を薄切し、グリア細胞線維性酸性タンパク質(GFAP)に対する免疫染色、脂肪染色、核染色及びニッスル染色を行った。
4日齢のラット個体を前処理液(チオジエタノール:30%スクロース=20:80)に4℃で24時間、最終溶液(チオジエタノール:グリセロール:30%スクロース=90:5:5)に4℃で48時間浸漬して透明化した。結果を図18に示す。ラット個体を丸ごと透明化できていることが確認される。
GFPを遺伝子導入したヒト肺癌細胞をヌードマウスの皮下に移植し、4週間成長させた。蛍光試薬を結合したトマトレクチンを動物の血管に注入した後、4%パラフォルムアルデヒド緩衝液で灌流固定した。癌組織を摘出し、4%パラフォルムアルデヒド緩衝液に24時間浸漬して固定した。
4%パラフォルムアルデヒド緩衝液で灌流固定した後にマウス脳を摘出し、さらに同溶液に24時間浸漬して固定した。固定後の脳(組織厚6mm)を、チオジエタノール:イオメプロール=50:50の溶液に25℃で48時間浸漬した。結果を図20Aに示す。
EGFPを発現するレトロウイルスベクターを用いてマウスの脳血管にEGFPを発現させた。実施例12と同様の手順で固定し透明化した脳を共焦点顕微鏡(Zeiss, LSA-700)により観察した。
4%パラフォルムアルデヒド緩衝液で灌流固定した後にラット脳を摘出し、さらに同溶液に24時間浸漬して固定した。固定後の脳(組織厚4mm)を、チオジエタノールに3日間浸漬した。
Claims (13)
- 2,2´-チオジエタノールと、グリセロール及び非イオン性有機ヨウ素化合物の少なくとも一方と、を含む水溶性溶媒中に組織を浸漬する手順を含む組織透明化方法。
- 前記溶媒が、2,2´-チオジエタノールとグリセロールと非イオン性有機ヨウ素化合物水溶液との混合液であり、2,2´-チオジエタノール、グリセロール及びヨウ素含有量40%の非イオン性有機ヨウ素化合物水溶液の容量比がそれぞれ10~50%、1~20%及び10~70%である請求項1記載の組織透明化方法。
- 前記溶媒が、2,2´-チオジエタノールと非イオン性有機ヨウ素化合物水溶液の混合液であり、2,2´-チオジエタノール及びヨウ素含有量40%の非イオン性有機ヨウ素化合物水溶液の容量比が20~80%、80~20%である請求項1記載の組織透明化方法。
- 前記溶媒が、2,2´-チオジエタノールとグリセロールとの混合液であり、2,2´-チオジエタノール及びグリセロールの容量比が70~95%、5~30%である請求項1記載の組織透明化方法。
- 前記溶媒が、さらにスクロース水溶液を含む請求項1記載の組織透明化方法。
- 前記溶媒の屈折率が、1.4~1.7である請求項1~5のいずれか一項に記載の組織透明化方法。
- 前記組織が、脳、脊髄、肝臓、肺、心臓、血管及び癌からなる群より選択される一以上である請求項1~6のいずれか一項に記載の組織透明化方法。
- 前記組織が1mm以上の厚さを有する請求項7記載の組織透明化方法。
- 2,2´-チオジエタノールと、グリセロール及び非イオン性有機ヨウ素化合物の少なくとも一方と、を含む水溶性溶媒からなる組織透明化試薬。
- 2,2´-チオジエタノールと、グリセロール及び非イオン性有機ヨウ素化合物の少なくとも一方と、を含む水溶性溶媒中に組織を浸漬する透明化手順を含む組織観察方法。
- 前記組織を蛍光標識する標識手順と、
蛍光標識後の前記組織を前記溶媒中に浸漬する前記透明化手順と、
透明化後の組織中の前記蛍光標識から発せられる蛍光を検出する検出手順と、を含む請求項10記載の組織観察方法。 - 前記組織を前記溶媒中に浸漬する前記透明化手順と、
透明化後の組織を蛍光標識する標識手順と、
透明化及び蛍光標識後の組織中の前記蛍光標識から発せられる蛍光を検出する検出手順と、を含む請求項10記載の組織観察方法。 - 前記検出手順において、前記蛍光を蛍光顕微鏡、蛍光実体顕微鏡、共焦点顕微鏡又は多光子顕微鏡により観察する請求項11又は12記載の組織観察方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014558293A JP6325461B2 (ja) | 2013-01-28 | 2013-11-20 | 組織透明化方法、組織透明化試薬及び組織観察方法 |
US14/764,060 US20160011086A1 (en) | 2013-01-28 | 2013-11-20 | Method for rendering tissue transparent, reagent for rendering tissue transparent, and tissue observation method |
CN201380071465.XA CN104956201B (zh) | 2013-01-28 | 2013-11-20 | 组织透明化方法、组织透明化试剂及组织观察方法 |
EP13872734.2A EP2950077B1 (en) | 2013-01-28 | 2013-11-20 | Method for rendering tissue transparent, reagent for rendering tissue transparent, and tissue observation method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013012889 | 2013-01-28 | ||
JP2013-012889 | 2013-01-28 | ||
JPPCT/JP2013/004369 | 2013-07-17 | ||
JP2013004369 | 2013-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014115206A1 true WO2014115206A1 (ja) | 2014-07-31 |
Family
ID=51227027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/006811 WO2014115206A1 (ja) | 2013-01-28 | 2013-11-20 | 組織透明化方法、組織透明化試薬及び組織観察方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20160011086A1 (ja) |
EP (1) | EP2950077B1 (ja) |
JP (1) | JP6325461B2 (ja) |
CN (1) | CN104956201B (ja) |
WO (1) | WO2014115206A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015030164A1 (ja) * | 2013-08-30 | 2015-03-05 | オリンパス株式会社 | 生体透明化剤 |
WO2016147812A1 (ja) * | 2015-03-18 | 2016-09-22 | 国立研究開発法人理化学研究所 | 生物材料の観察方法および透明化方法 |
CN107132101A (zh) * | 2017-03-28 | 2017-09-05 | 中国科学院深圳先进技术研究院 | 一种组织光透明剂及其制备方法和应用 |
JPWO2016103425A1 (ja) * | 2014-12-25 | 2017-10-05 | オリンパス株式会社 | 生体観察装置および生体観察方法 |
WO2017188264A1 (ja) * | 2016-04-28 | 2017-11-02 | 国立研究開発法人理化学研究所 | 光透過性に優れた生物材料を調製するための組成物およびその利用 |
WO2018008136A1 (ja) * | 2016-07-07 | 2018-01-11 | オリンパス株式会社 | 画像処理装置および画像処理装置の作動方法 |
JP2018063216A (ja) * | 2016-10-14 | 2018-04-19 | 株式会社ファンケル | 皮膚内部構造評価方法 |
KR20180060494A (ko) * | 2016-11-29 | 2018-06-07 | 박순현 | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 |
WO2019094753A1 (en) * | 2017-11-09 | 2019-05-16 | Case Western Reserve University | Lipid-preserving refractive index matching for prolonged imaging depth for transparent tissue sample and composition |
WO2019180874A1 (ja) * | 2018-03-22 | 2019-09-26 | オリンパス株式会社 | 生体組織透明化材料 |
CN110763661A (zh) * | 2018-07-25 | 2020-02-07 | 中国科学院合肥物质科学研究院 | 处理液组合物、试剂盒和生物器官透明化同时进行免疫标记的方法 |
JP2020034297A (ja) * | 2018-08-27 | 2020-03-05 | 学校法人東京理科大学 | 生体試料の透明化方法及び生体試料透明化剤 |
WO2021015196A1 (ja) * | 2019-07-22 | 2021-01-28 | 国立大学法人 東京大学 | 生体組織の処理方法及び処理用組成物 |
WO2021060373A1 (ja) * | 2019-09-24 | 2021-04-01 | 国立大学法人大阪大学 | 細胞適合性組織透明化組成物 |
JP2021512330A (ja) * | 2018-02-05 | 2021-05-13 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | スフェロイドを透明化するための組成物、これを使用するスフェロイドを透明化するための方法、およびこれを備えるキット |
WO2021182121A1 (ja) * | 2020-03-13 | 2021-09-16 | 学校法人慈恵大学 | バイオフィルムの透明化試薬、及び、その透明化試薬を使用するバイオフィルムの観察方法 |
WO2021238893A1 (en) * | 2020-05-25 | 2021-12-02 | The Chinese University Of Hong Kong | Efficient and effective tissue clearing agents and their compositions |
WO2024162288A1 (ja) * | 2023-01-31 | 2024-08-08 | 国立研究開発法人理化学研究所 | 光学観察用の構造及びその作成方法、試料の観察方法、顕微鏡観察用のマウント液 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170160170A1 (en) * | 2014-07-07 | 2017-06-08 | Chih-Yung Lin | Aqueous tissue clearing solution and uses thereof |
CN107621462B (zh) * | 2016-07-13 | 2020-03-31 | 王志伟 | 一种组织透明化液sut及其制备和应用 |
CN106323708B (zh) * | 2016-07-29 | 2019-04-30 | 浙江大学 | 一种透明化试剂、生物组织透明化成像方法及其应用 |
WO2018113723A1 (en) * | 2016-12-22 | 2018-06-28 | The University Of Hong Kong | Compositions and methods for clearing tissue |
CN109406768B (zh) * | 2018-11-06 | 2023-01-24 | 扬州大学 | 一种观察微小组织内细胞立体分布及统计细胞数目的方法 |
CN114402060A (zh) * | 2019-07-08 | 2022-04-26 | 香港大学 | 用于组织透明化的组合物和方法 |
CN110596096B (zh) * | 2019-07-08 | 2022-10-25 | 深圳技术大学 | 透明化试剂及其在生物组织材料光学成像中的应用、活体皮肤组织透明化成像方法 |
CN111610078B (zh) * | 2020-07-03 | 2021-12-14 | 中国科学技术大学 | 生物组织透明化试剂及生物组织透明化方法 |
CN117147250B (zh) * | 2023-08-16 | 2024-06-04 | 四川大学 | 一种实验用小型哺乳动物牙齿透明化方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11187900A (ja) * | 1997-08-01 | 1999-07-13 | Canon Inc | プローブの固相へのスポッティング方法、プローブアレイとその製造方法、及びそれを用いた標的物質の検出方法、標的物質の構造の特定化方法 |
US6472216B1 (en) * | 2001-07-24 | 2002-10-29 | Ann-Shyn Chiang | Aqueous tissue clearing solution |
JP2007051957A (ja) * | 2005-08-18 | 2007-03-01 | Shimadzu Corp | 生体組織の直接質量分析法 |
WO2011111876A1 (en) * | 2010-03-12 | 2011-09-15 | Riken | Clearing reagent for biological material, and use thereof |
WO2012147965A1 (ja) * | 2011-04-28 | 2012-11-01 | 独立行政法人理化学研究所 | 生物材料を透明化する方法、及びその利用 |
WO2012161143A1 (ja) * | 2011-05-20 | 2012-11-29 | 独立行政法人理化学研究所 | 生物材料用透明化試薬、及びその利用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6219575B1 (en) * | 1998-10-23 | 2001-04-17 | Babak Nemati | Method and apparatus to enhance optical transparency of biological tissues |
JP3486609B2 (ja) * | 2000-12-15 | 2004-01-13 | キヤノン株式会社 | インク、インクジェット記録方法、記録ユニット、インクカートリッジ及びインクジェット記録装置 |
GB2377757B (en) * | 2001-07-19 | 2004-11-17 | Ann-Shyn Chiang | An aqueous tissue clearing solution |
CN101251449A (zh) * | 2008-04-10 | 2008-08-27 | 山东大学 | 一种医学组织切片染色方法 |
CN102749231B (zh) * | 2011-10-14 | 2014-07-09 | 华中科技大学 | 骨组织光透明剂 |
-
2013
- 2013-11-20 US US14/764,060 patent/US20160011086A1/en active Pending
- 2013-11-20 JP JP2014558293A patent/JP6325461B2/ja active Active
- 2013-11-20 EP EP13872734.2A patent/EP2950077B1/en active Active
- 2013-11-20 WO PCT/JP2013/006811 patent/WO2014115206A1/ja active Application Filing
- 2013-11-20 CN CN201380071465.XA patent/CN104956201B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11187900A (ja) * | 1997-08-01 | 1999-07-13 | Canon Inc | プローブの固相へのスポッティング方法、プローブアレイとその製造方法、及びそれを用いた標的物質の検出方法、標的物質の構造の特定化方法 |
US6472216B1 (en) * | 2001-07-24 | 2002-10-29 | Ann-Shyn Chiang | Aqueous tissue clearing solution |
JP2007051957A (ja) * | 2005-08-18 | 2007-03-01 | Shimadzu Corp | 生体組織の直接質量分析法 |
WO2011111876A1 (en) * | 2010-03-12 | 2011-09-15 | Riken | Clearing reagent for biological material, and use thereof |
JP2013522590A (ja) | 2010-03-12 | 2013-06-13 | 独立行政法人理化学研究所 | 生物材料用透明化試薬、及びその利用 |
WO2012147965A1 (ja) * | 2011-04-28 | 2012-11-01 | 独立行政法人理化学研究所 | 生物材料を透明化する方法、及びその利用 |
WO2012161143A1 (ja) * | 2011-05-20 | 2012-11-29 | 独立行政法人理化学研究所 | 生物材料用透明化試薬、及びその利用 |
Non-Patent Citations (10)
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015030164A1 (ja) * | 2013-08-30 | 2015-03-05 | オリンパス株式会社 | 生体透明化剤 |
JPWO2016103425A1 (ja) * | 2014-12-25 | 2017-10-05 | オリンパス株式会社 | 生体観察装置および生体観察方法 |
WO2016147812A1 (ja) * | 2015-03-18 | 2016-09-22 | 国立研究開発法人理化学研究所 | 生物材料の観察方法および透明化方法 |
JPWO2016147812A1 (ja) * | 2015-03-18 | 2017-12-28 | 国立研究開発法人理化学研究所 | 生物材料の観察方法および透明化方法 |
US20180031452A1 (en) * | 2015-03-18 | 2018-02-01 | Riken | Method for observing biological material and clearing method |
JPWO2017188264A1 (ja) * | 2016-04-28 | 2019-04-11 | 国立研究開発法人理化学研究所 | 光透過性に優れた生物材料を調製するための組成物およびその利用 |
US11656159B2 (en) | 2016-04-28 | 2023-05-23 | Riken | Composition for preparing biological material having excellent light transmissivity and use of composition |
WO2017188264A1 (ja) * | 2016-04-28 | 2017-11-02 | 国立研究開発法人理化学研究所 | 光透過性に優れた生物材料を調製するための組成物およびその利用 |
WO2018008136A1 (ja) * | 2016-07-07 | 2018-01-11 | オリンパス株式会社 | 画像処理装置および画像処理装置の作動方法 |
US10921252B2 (en) | 2016-07-07 | 2021-02-16 | Olympus Corporation | Image processing apparatus and method of operating image processing apparatus |
JP2018063216A (ja) * | 2016-10-14 | 2018-04-19 | 株式会社ファンケル | 皮膚内部構造評価方法 |
KR20180060494A (ko) * | 2016-11-29 | 2018-06-07 | 박순현 | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 |
KR101866249B1 (ko) * | 2016-11-29 | 2018-06-12 | 박순현 | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 |
US11726012B2 (en) | 2016-11-29 | 2023-08-15 | Binaree, Inc. | Composition for biotissue clearing and biotissue clearing method using same |
CN107132101B (zh) * | 2017-03-28 | 2019-10-11 | 中国科学院深圳先进技术研究院 | 一种组织光透明剂及其制备方法和应用 |
CN107132101A (zh) * | 2017-03-28 | 2017-09-05 | 中国科学院深圳先进技术研究院 | 一种组织光透明剂及其制备方法和应用 |
AU2018364670B2 (en) * | 2017-11-09 | 2020-06-11 | Case Western Reserve University | Lipid-preserving refractive index matching for prolonged imaging depth for transparent tissue sample and composition |
WO2019094753A1 (en) * | 2017-11-09 | 2019-05-16 | Case Western Reserve University | Lipid-preserving refractive index matching for prolonged imaging depth for transparent tissue sample and composition |
JP2021512330A (ja) * | 2018-02-05 | 2021-05-13 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | スフェロイドを透明化するための組成物、これを使用するスフェロイドを透明化するための方法、およびこれを備えるキット |
US11365213B2 (en) | 2018-02-05 | 2022-06-21 | Korea Research Institute Of Chemical Technology | Composition for clearing spheroids, method for clearing spheroids using same, and kit comprising same |
JP7053860B2 (ja) | 2018-02-05 | 2022-04-12 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | スフェロイドを透明化するための組成物、これを使用するスフェロイドを透明化するための方法、およびこれを備えるキット |
WO2019180874A1 (ja) * | 2018-03-22 | 2019-09-26 | オリンパス株式会社 | 生体組織透明化材料 |
CN110763661B (zh) * | 2018-07-25 | 2022-03-22 | 中国科学院合肥物质科学研究院 | 处理液组合物、试剂盒和生物器官透明化同时进行免疫标记的方法 |
CN110763661A (zh) * | 2018-07-25 | 2020-02-07 | 中国科学院合肥物质科学研究院 | 处理液组合物、试剂盒和生物器官透明化同时进行免疫标记的方法 |
JP7106114B2 (ja) | 2018-08-27 | 2022-07-26 | 学校法人東京理科大学 | 生体試料の透明化方法及び生体試料透明化剤 |
JP2020034297A (ja) * | 2018-08-27 | 2020-03-05 | 学校法人東京理科大学 | 生体試料の透明化方法及び生体試料透明化剤 |
WO2021015196A1 (ja) * | 2019-07-22 | 2021-01-28 | 国立大学法人 東京大学 | 生体組織の処理方法及び処理用組成物 |
WO2021060373A1 (ja) * | 2019-09-24 | 2021-04-01 | 国立大学法人大阪大学 | 細胞適合性組織透明化組成物 |
WO2021182121A1 (ja) * | 2020-03-13 | 2021-09-16 | 学校法人慈恵大学 | バイオフィルムの透明化試薬、及び、その透明化試薬を使用するバイオフィルムの観察方法 |
WO2021238893A1 (en) * | 2020-05-25 | 2021-12-02 | The Chinese University Of Hong Kong | Efficient and effective tissue clearing agents and their compositions |
WO2024162288A1 (ja) * | 2023-01-31 | 2024-08-08 | 国立研究開発法人理化学研究所 | 光学観察用の構造及びその作成方法、試料の観察方法、顕微鏡観察用のマウント液 |
Also Published As
Publication number | Publication date |
---|---|
EP2950077A4 (en) | 2016-11-02 |
JP6325461B2 (ja) | 2018-05-16 |
EP2950077A1 (en) | 2015-12-02 |
US20160011086A1 (en) | 2016-01-14 |
JPWO2014115206A1 (ja) | 2017-01-19 |
CN104956201B (zh) | 2018-08-28 |
CN104956201A (zh) | 2015-09-30 |
EP2950077B1 (en) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6325461B2 (ja) | 組織透明化方法、組織透明化試薬及び組織観察方法 | |
Azaripour et al. | A survey of clearing techniques for 3D imaging of tissues with special reference to connective tissue | |
US11035763B2 (en) | Kit for producing cleared biological specimens and method for producing cleared biological specimens | |
US9778155B2 (en) | Methods for phenotyping of intact whole tissues | |
JP2024019174A (ja) | 大型組織の標識、透明化及びイメージングのための方法 | |
EP3550029B1 (en) | Composition for biotissue clearing and biotissue clearing method using same | |
Williams et al. | A novel optical tissue clearing protocol for mouse skeletal muscle to visualize endplates in their tissue context | |
CN104568553B (zh) | 一种组织光透明剂及其应用 | |
KR102296381B1 (ko) | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 | |
CN107132101A (zh) | 一种组织光透明剂及其制备方法和应用 | |
WO2021015196A1 (ja) | 生体組織の処理方法及び処理用組成物 | |
DE102007003873A1 (de) | Verfahren zur Fluoreszenzfärbung von Gewebe | |
KR102141496B1 (ko) | 투명화된 거대조직의 면역염색용 조성물 및 이를 이용한 투명화된 거대 생체 조직의 면역염색 방법 | |
JP7411223B2 (ja) | 被検体の透明化方法および透明化された被検体の製造方法 | |
CN114149693B (zh) | 一种用于血管网络标记成像的染料工作液、其制备和应用 | |
TWI695846B (zh) | 固化式組織澄清方法與組合物 | |
RU2429462C2 (ru) | Способ оптического просветления образцов биологических тканей | |
KR102354092B1 (ko) | 스페로이드 투명화용 조성물, 이를 이용한 스페로이드 투명화 방법 및 이를 포함하는 키트 | |
Montoro et al. | Comparison of tissue processing methods for microvascular visualization in axolotls | |
RU2494681C1 (ru) | Способ оценки кровоснабжения левой половины толстого кишечника в эксперименте | |
Heimel et al. | Research Article Iodine-Enhanced Micro-CT Imaging of Soft Tissue on the Example of Peripheral Nerve Regeneration | |
Matryba et al. | Progress in ex situ tissue optical clearing–shifting immuno-oncology to the third dimension | |
Grafflin et al. | Autofluorescence of teleostean kidneys |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13872734 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014558293 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013872734 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14764060 Country of ref document: US |